Amendments to the Claims

The following listing of claims will replace all prior versions and listings of claims in the application.

1-9. (Canceled)

10. (Currently Amended) A pharmaceutical composition comprising a compound of formula (I'),



(I')

wherein Y and R^2 are as defined in claim 11

or a pharmaceutically-acceptable salt or solvate thereof, ~~as defined in claim 8~~ **for the use in treatment of mycobacterial tuberculosis,** in association with a pharmaceutically-acceptable adjuvant, diluent or carrier.

11. (Currently Amended) A method of treating a patient suffering from, or at risk of, **mycobacterial tuberculosis** ~~a mycobacterial disease~~, which comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically-acceptable salt or solvate thereof, ~~as defined in any one of claims 1 to 7.~~



(I)

wherein x represents 0 or 1, R^1 represents a 3- to 7-membered (hetero)cycloalkyl group or a phenyl group, Y represents a group CH_2 or >C=O, and R^2 represents either a C_1-C_{12} alkyl group optionally substituted by one or more halogen atoms,
a group



(A)

wherein m represents an integer from 3 to 7, R^3 represents a C_1-C_6 alkyl group and
R^4 represents a cyclohexyl or phenyl group optionally substituted by one or more substituents selected from the group consisting of a halogen atom, C_1-C_6 alkyl and
C_1-C_6 alkoxy group,
or a group



(B)

wherein n represents an integer from 2 to 4, p and q independently represent an integer from 1 to 2, Z represents N or CH and R^5 represents a cyclohexyl or phenyl group optionally

substituted by one or more substituents selected from the group consisting of a halogen atom, C_1-C_6 alkyl and C_1-C_6 alkoxy group.

12. (New) The method according to claim 11, wherein Y represents a group >C=O.

13. (New) The method according to claim 11, wherein R^1 represents a 5- to 7-membered (hetero)cycloalkyl group or a phenyl group.

14. (New) The method according to claim 11, wherein R^1 is located in the 5- or 7-position.

15. (New) The method according to claim 11, wherein R^2 represents either a C_4-C_{12} alkyl group, a group (A) in which R^4 represents a phenyl group and m and R^3 are as defined in claim 1, or a group (B) in which n is 2, p is 1, q is 1, Z is N or CH and R^5 represents a phenyl group.

16. (New) The method according to claim 11, wherein the compound is:
5-Cyclohexyl-1-[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]-1H-indole-2,3-dione;
7-Cycloheptyl-1-[2-[4-(phenylmethyl)-1-piperazinyl]ethyl]-1H-indole-2,3-dione;
5-Cyclohexyl-1-(5-(N-ethyl-N-phenylmethylamino)pentyl)-1H-indole-2,3-dione;
5-Cyclohexyl-1,3-dihydro-1-[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]-2H-indol-2-one;
1-(4-(N-Ethyl-N-phenylmethylamino)butyl)-1H-indole-2,3-dione;

5-Phenyl-1-[2-[4-(phenylmethyl)-1-piperazinyl]ethyl]-1H-indole-2,3-dione;

7-Cyclopentyl-1-[2-[4-(phenylmethyl)-1-piperazinyl]ethyl]-1H-indole-2,3-dione;

5-(1-Piperidinyl)-1-[2-[4-(phenylmethyl)-1-piperazinyl]ethyl]-1H-indole-2,3-dione;

1-(4-Bromobutyl)-5-cyclohexyl-1H-indole-2,3-dione;

1-Nonyl-7-phenyl-1H-indole-2,3-dione;

1-Heptyl-7-phenyl-1H-indole-2,3-dione;

1-Octyl-7-phenyl-1H-indole-2,3-dione;

1-Decyl-7-phenyl-1H-indole-2,3-dione;

1-Undecyl-7-phenyl-1H-indole-2,3-dione;

1-Pentyl-7-phenyl-1H-indole-2,3-dione;

1-Butyl-7-phenyl-1H-indole-2,3-dione;

1-(2-Methylpropyl)-7-phenyl-1H-indole-2,3-dione;

1-Hexyl-7-phenyl-1H-indole-2,3-dione;

1-Dodecyl-7-phenyl-1H-indole-2,3-dione; or

1-(4-Bromobutyl)-7-phenyl-1H-indole-2,3-dione in the form of the free base, or a pharmaceutically acceptable salt or solvate thereof.